This is a StreetInsider.com Premium Only Page

(LEXX) –

Apr 24, 2024 11:39 AM Form 8-K Lexaria Bioscience Corp. For: Apr 23

Apr 16, 2024 09:11 AM Lexaria Bioscience (LEXX) Receives Approval to Begin New GLP-1 Study

Apr 16, 2024 09:10 AM Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Apr 16, 2024 08:10 AM Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Apr 9, 2024 04:12 PM Form 10-Q Lexaria Bioscience Corp. For: Feb 29

Apr 2, 2024 09:01 AM Lexaria Bioscience (LEXX) Granted Three New Patents

Apr 2, 2024 09:00 AM Lexaria Awarded New Patents

Apr 2, 2024 08:00 AM Lexaria Awarded New Patents

Mar 21, 2024 04:39 PM Form 8-K Lexaria Bioscience Corp. For: Mar 15

Mar 21, 2024 09:20 AM Lexaria to Present at The LD Micro Invitational XIV

Mar 21, 2024 06:03 AM Form EFFECT Lexaria Bioscience Corp.

Mar 20, 2024 05:01 PM Form 424B3 Lexaria Bioscience Corp.

Mar 15, 2024 04:26 PM Form 3 Lexaria Bioscience Corp. For: Mar 14 Filed by: Cabatuan Nelson

Mar 15, 2024 04:10 PM Form 8-K Lexaria Bioscience Corp. For: Mar 14

Mar 14, 2024 09:20 AM Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Mar 14, 2024 09:11 AM Lexaria Bioscience (LEXX) Appoints Nelson Cabatuan as Chief Financial Officer

Mar 14, 2024 08:10 AM Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Mar 12, 2024 05:12 PM Lexaria Bioscience (LEXX) Announces 1.61M Share Offering by Selling Stockholders

Mar 12, 2024 05:10 PM Form S-1 Lexaria Bioscience Corp.

Mar 7, 2024 09:06 AM Lexaria Bioscience (LEXX) Awards Contract For Next GLP-1 Human Pilot Study

Mar 7, 2024 09:05 AM Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Mar 7, 2024 08:05 AM Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Mar 6, 2024 06:02 AM Form DEF 14A Lexaria Bioscience Corp. For: Feb 27

Mar 5, 2024 09:05 AM Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

Mar 5, 2024 05:05 AM Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

Mar 4, 2024 09:15 AM 7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

Mar 4, 2024 08:15 AM 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study

Mar 4, 2024 08:15 AM 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study

Mar 1, 2024 02:28 PM Form 8-K Lexaria Bioscience Corp. For: Feb 29

Mar 1, 2024 08:21 AM Lexaria Bioscience (LEXX) Announces FDA Clearance for Planned US Phase 1b Hypertension Trial

Mar 1, 2024 08:20 AM Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Mar 1, 2024 07:20 AM Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Feb 16, 2024 06:00 PM Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Feb 16, 2024 04:32 PM Form 8-K Lexaria Bioscience Corp. For: Feb 14

Feb 16, 2024 04:05 PM Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Feb 16, 2024 03:48 PM Form D Lexaria Bioscience Corp.

Feb 16, 2024 06:03 AM Form 424B5 Lexaria Bioscience Corp.

Feb 15, 2024 08:02 AM Lexaria Bioscience (LEXX) Announces 1.56M Share Offering at $2.31/sh

Feb 15, 2024 08:00 AM Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Feb 14, 2024 02:21 PM Form SC 13D/A Lexaria Bioscience Corp. Filed by: Boos Wayne W

Feb 14, 2024 12:00 PM Form SC 13G/A Lexaria Bioscience Corp. Filed by: Invenomic Capital Management LP

Jan 30, 2024 01:51 PM Form 8-K Lexaria Bioscience Corp. For: Jan 29

Jan 30, 2024 08:48 AM Lexaria Bioscience (LEXX) Submits Investigational NDA for Phase 1B HYPER-H23-1 Trial

Jan 30, 2024 08:45 AM Lexaria's Submits Investigational New Drug Application

Jan 29, 2024 06:04 AM Form EFFECT Lexaria Bioscience Corp.

Jan 24, 2024 02:12 PM Form 8-K Lexaria Bioscience Corp. For: Jan 24

Jan 24, 2024 01:34 PM Form POS AM Lexaria Bioscience Corp.

Jan 24, 2024 08:48 AM Lexaria Bioscience (LEXX) CEO Issues Letter to Shareholders

Jan 24, 2024 08:45 AM Lexaria Releases Annual Letter from the CEO

Jan 18, 2024 02:39 PM Form S-8 Lexaria Bioscience Corp.